Previous Article | Next Article 
Infection and Immunity, April 2000, p. 2069-2076, Vol. 68, No. 4
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Interleukin-12 Neutralization Alters Lung
Inflammation and Leukocyte Expression of CD80, CD86, and Major
Histocompatibility Complex Class II in Mice Infected with
Histoplasma capsulatum
Judith A.
Cain and
George S.
Deepe Jr.*
Department of Medicine, Division of
Infectious Diseases, University of Cincinnati College of Medicine,
Cincinnati, Ohio 45267-0560, and Veterans Affairs Hospital, Cincinnati,
Ohio 48229
Received 11 October 1999/Returned for modification 2 December
1999/Accepted 4 January 2000
 |
ABSTRACT |
Histoplasma capsulatum induces a cell-mediated immune
response in lungs and lymphoid organs of mammals. Resolution of primary infection in mice depends on interleukin-12 (IL-12), since
neutralization of this monokine increases susceptibility to infection.
The present study was designed to determine if blockade of IL-12
disrupts the protective immune response by altering the influx of
lineage-specific cells into infected lungs and the numbers of cells
expressing CD80, CD86, CD119, and major histocompatibility complex
class II (MHC II) molecules. In mice given anti-IL-12, there was a
2.5-fold decrease in total numbers of T cells on days 3 to 10 of
infection and a 4-fold increase in Mac-1/Gr-1+ cells on
days 7 and 10 compared to infected controls. CD80+ lung
cells from anti-IL-12-treated mice were 2- to 3-fold greater than those
from controls on days 7 and 10, whereas the total numbers of
CD86+ cells were 2- to 3-fold less and MHC II+
cells were 1.5- to 2-fold less on days 3 and 5. Cells expressing CD119
were reduced 1.5-fold on day 5. Treatment with monoclonal antibodies
(MAb) to CD80, CD86, or both reduced the fungal burden slightly
compared to that in rat immunoglobulin G-treated controls, whereas
after IL-12 neutralization, blocking of CD80 reduced the tissue burden
by 2.5-fold and this correlated with a decrease in IL-4. Regardless,
mortality was not altered by treatment with MAb to CD80 or CD86. We
conclude that (i) IL-12 neutralization alters the nature of the
inflammatory response in lungs and the expression of CD80 and CD86 on
lineage-specific cells, (ii) the immune response during infection with
H. capsulatum is controlled via mechanisms independent of
the CD80 and CD86 costimulatory pathways, and (iii) decreased
expression of CD86 and MHC II may modulate generation of optimal
protective immunity.
 |
INTRODUCTION |
Histoplasma capsulatum is
an intracellular pathogenic fungus that is responsible for mild disease
in immunocompetent hosts and a progressive and fatal disease if
untreated in immunocompromised hosts (7). The initial site
of infection is the lung, where yeast cells, produced from inhaled
microconidia, are ingested by alveolar macrophages (M
) via an
interaction between the CD11/CD18 family of adhesion molecules and
yeast cell wall components (4). Phagocytosis of yeast cells
by M
results in a permissive environment for survival and
replication of yeasts. Resistance to H. capsulatum infection
in mammals is primarily dependent on a cellular immune response
mediated by T cells and phagocytes. Resolution of infection in mice
requires the production of cytokines, especially gamma interferon
(IFN-
) (1, 30, 33), and release of this cytokine by NK
and T cells is dependent on the pathogen-induced release of the
monokine interleukin-12 (IL-12) (26). H. capsulatum infection of mice with a genetic absence of IFN-
or
those given antibodies (Ab) to IL-12 results in an uncontrollable and
fatal fungal burden (1, 2, 33). IL-12 release is necessary
for M
to kill yeasts before day 5 of infection, since animals
depleted of IL-12 beyond this point survive the infection
(1).
The purpose of this study was to determine if neutralization of IL-12
and subsequent IFN-
depletion altered the expression of cell surface
molecules involved in the generation of protective cell-mediated
immunity. The molecules CD80, CD86, major histocompatibility complex
class II (MHC II), and CD119 (IFN-
receptor) were chosen for
analysis because of their potential contribution to an effector cell-mediated immune response to H. capsulatum. We assessed
if blockade of IL-12 altered the number of cells that express these molecules and their surface density.
 |
MATERIALS AND METHODS |
Mice.
Male C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, Maine) and maintained in the animal facility at
the University of Cincinnati. All experiments used animals that were 6 to 12 weeks of age. Control and infected mice were housed in laminar
flow units. Athymic nude mice were purchased from the National Cancer
Institute (Frederick, Md.).
Preparation of yeast cultures and i.n. infection of mice.
H. capsulatum yeast cells (strain G217B) were grown in 50 ml
of Ham's F-12 medium supplemented with glucose (18.2 g/liter), glutamic acid (1 g/liter), HEPES (6 g/liter), and cysteine (8.4 mg/liter) for 48 h at 37°C. Cell suspensions were prepared by two washes with Hanks' balanced salt solution (HBSS) containing 0.2 M
HEPES and 0.5% bovine serum albumin (BSA) followed by a third wash at
100 × g. The final volume was adjusted to equal 2.5 × 106 or 0.6 × 106 yeast cells
per 50 µl of buffer. Mice anesthetized with Metophane (Pitman-Moore,
Mundelein, Ill.) were infected intranasally (i.n.) with 50 µl of
yeast suspension. Control animals were given equal volumes of buffer alone.
Enumeration of yeast burden in infected tissues.
Spleens and
lungs from mice were removed at selected intervals during infection and
homogenized in 10 ml HBSS, and 100-µl portions of serial dilutions
were streaked onto 150-mm-diameter plates containing 3.7% brain heart
infusion (Difco, Detroit, Mich.), 1% glucose, 0.01% cysteine
hydrochloride (Sigma, St. Louis, Mo.), 2% agar (Difco), 5 mg of
gentamicin (Sigma) per ml, and 5% defibrinated sheep erythrocytes
(Colorado Serum Co., Denver, Colo.). Plates were incubated at 30°C,
and CFU were enumerated after 7 days.
Ab and immunofluorescent reagents.
Fluorescein
isothiocyanate (FITC)-conjugated monoclonal Ab (MAb) to CD45 (clone
30F11.1), CD45R/B220 (clone RA3-6B2), CD90.2 (Thy-1, clone 30-H12), and
Ly-6G/Gr-1 (clone RB6-8C5); biotin-conjugated MAb to CD119 (IFN-
receptor, clone GR20), CD86 (clone GL-1), and anti-mouse
I-Ab (clone AF6-120.1); phycoerythrin-conjugated CD80
(clone IG-10); and streptavidin-phycoerythrin (SAv-PE) were purchased
from Pharmingen (San Diego, Calif.). Ab produced by the anti-Mac-1
hybridoma (anti-CR3, clone M1/70) was purified from tissue culture
supernatant with a protein G affinity column (Pharmacia, Piscataway,
N.J.) and conjugated to FITC as previously reported (13).
Purification of Ab for depletion experiments.
Rat hybridomas
producing MAb to murine CD80 (B7-1, clone IG-10) and CD86 (B7-2, clone
GL-1) were purchased from the American Type Culture Collection,
Rockville, Md. Purification was accomplished by passing tissue culture
supernatants over an anti-bovine immunoglobulin (Ig) Sepharose column
in tandem with a protein G (Pharmacia) affinity column, followed by
elution with 0.1 M glycine-HCl, pH 2.8. After concentration, the Ab was
dialyzed against HBSS and filter sterilized. Alternatively, hybridoma
cells were injected into pristane-primed nude mice, and ascites fluid
was collected and purified by the capryllic acid-ammonium sulfate
method (16). Purified Ab was dialyzed against HBSS, filter
sterilized, and stored at
20°C until use. Ab against murine IL-12
(clones 15.1 and 15.6) were prepared as previously described
(1).
Treatment of mice with MAb.
For IL-12 neutralization
studies, mice were injected intraperitoneally with a mixture of 250 µg each of MAb 15.1 and 15.6 1 day before infection and on days 1, 3, 7, and 14 of infection as previously described (1). For
experiments designed to examine the effects of CD80 and CD86 blockade,
animals were injected i.n. with 200 µg of either anti-CD80 or
anti-CD86 or a mixture of both in a final volume of 50 µl 1 day
before infection and on days 1, 3, 5, 7, 10, 14, and 17 of infection.
This dose of MAb has been reported to block function (27).
Determination of cytokine levels in infected lungs.
Tissue
homogenates or single-cell suspensions from lungs of infected animals
used for CFU analyses were centrifuged at 700 × g for
10 min, and supernatants were collected and stored at
70°C until
use. Enzyme-linked immunosorbent assay kits for the detection of
IFN-
, IL-4, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and tumor necrosis factor alpha (TNF-
) were purchased from
Endogen (Woburn, Mass.), and analysis was performed according to the
manufacturer's instructions.
Preparation of single-cell suspension from lung tissue.
Lungs from infected animals were removed on days 3, 5, 7, 10, 14, and
21 of infection, initially crushed with a 10-ml syringe plunger, teased
apart with forceps, and suspended in RPMI medium containing glutamine
(0.29 mg/ml), penicillin, streptomycin (100 U/ml, 100 mg/ml), and 10%
fetal bovine serum. The organs were homogenized into single-cell
suspensions by sequential passage through 16-, 18-, and 20-gauge
needles. The mononuclear fraction was isolated by separation on 40 to
70% Percoll gradients (Pharmacia). For surface phenotyping, cells were
resuspended in phosphate-buffered saline (pH 7.3) containing 1% BSA
and 0.1% azide.
Cell surface phenotype.
Cells isolated from lungs were
pelleted (1 × 105 to 5 × 105) at
350 × g and incubated with a saturating amount of Ab
for 15 min at 4°C. Cells were washed twice with phosphate-buffered
saline containing 1% BSA and 0.1% azide before addition of SAv-PE for biotinylated reagents followed by incubation and washing as before. For
two-color analyses, cells were incubated with FITC-conjugated lineage-specific MAb, washed, and then incubated with
phycoerythrin-conjugated CD80 or CD86-biotin and SAv-PE and then washed
as before. All samples were resuspended in a 1% paraformaldehyde
solution before analysis on a FACSCalibur flow cytometer (Becton
Dickinson, Mountain View, Calif.). Flow cytometry data, reported as
percent positive cells and mean fluorescence intensity (MFI), were
determined with Cell Quest analysis software. Changes in the density of
surface antigens can be determined by flow cytometry by measuring MFI values. In order to compare data from several experiments, these values
were calculated as the fold increase in fluorescence intensity of the
positive population over the MFI of the negative cells. This analysis
corrects for variations in baseline values that fluctuate because of
autofluorescence or nonspecific MAb interactions.
The absolute number of cells expressing each surface marker was
calculated by multiplying the percent positive cells of each phenotype
by the total number of cells derived from the Percoll gradients. Since
cell types other than blood lineage cells were present within analysis
gates that contained the total population of live cells, the data were
normalized to represent hemopoietic lineage cells within the gate by
multiplying by the percentage of CD45+ cells. This Ab
(clone 30F11.1) recognizes all blood cells except erythrocytes
(22).
Statistical analyses.
Student's t test was
used to analyze differences in total numbers of cells expressing a
certain phenotype, fungal burdens, and cytokine levels.
 |
RESULTS |
Enumeration of cells isolated from infected lungs.
The total
cell numbers in lungs of anti-IL-12-treated mice that were infected
with 2.5 × 106 yeasts were significantly greater than
those in control animals on days 7 and 10 of infection (P
0.01 and 0.02, respectively) (Table
1). The total numbers of cells from
anti-IL-12-treated animals after day 10 were not available, since 100%
of these animals succumbed to infection and died before day 14. The
mean survival time for these mice was 13.1 ± 0.9 days.
Analysis of cells expressing phenotypic markers in lungs of
control and anti-IL-12-treated mice.
Lungs from infected mice
treated with anti-IL-12 or rat IgG were removed on days 3, 5, 7, 10, 14, and 21 of infection for controls (rat IgG) or through day 10 for
IL-12-neutralized animals and analyzed by flow cytometry for expression
of surface markers. The lymphocyte populations of cells were reduced in
numbers after IL-12 neutralization, whereas myeloid lineage cell
numbers increased (Fig. 1). A comparison
of the absolute numbers of T cells in lungs from rat Ig- and
anti-IL-12-treated mice revealed that this population of cells was
decreased 1.5- to 2.5-fold in the latter group. These reduced numbers
of T cells were significantly different from those for rat IgG controls
on all days analyzed (days 3, 5, 7, and 10; P
0.027,
0.008, 0.014, and 0.022, respectively). B cells also were significantly
less after IL-12 neutralization on day 5 (2.5-fold; P
0.046) and day 7 (3-fold; P
0.046) (data not
shown). After IL-12 neutralization a threefold increase in numbers of
myeloid-lineage cells in lungs was observed on days 7 and 10 of
infection (P
0.001 and P
0.033,
respectively), as well as a fourfold increase in Gr-1+
cells on day 7 (P
0.008) and fivefold greater
numbers on day 10 (P
0.05).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of the modulation of lineage-specific
cells after IL-12 neutralization. Flow cytometry data for the
percentages of positive cells were corrected for the percentage of
CD45+ cells within the analysis gate. The data from two
experiments were expressed as the mean of the total number of cells
expressing each marker (± standard error) for five to nine animals per
group. Asterisks indicate data that were significantly different for
control and anti-IL-12-treated mice (P 0.05). Data
for day 0 were from uninfected (naive) mice (n = 5).
|
|
The effect of IL-12 neutralization on the numbers of cells expressing
the accessory molecules CD80 and CD86 differed in that
the numbers of
CD80
+ cells increased on day 7 (3.5-fold;
P 
0.001) and day 10 (2.5-fold;
P 
0.004), whereas
the numbers of CD86
+ cells were depressed by approximately
threefold on days 3 (
P 
0.01) and 5 (
P 
0.006) but were similar to control values by
day 7 (Fig.
2).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
Modulation of the number of lung cells expressing CD80,
CD86, MHC II, and CD119 after administration of anti-IL-12. The total
number of cells was calculated from the percent-positive data for each
marker on days 3, 5, 7, 10, 14, and 21. Data for day 0 were from
uninfected (naive) mice (n = 5). The data from two
experiments were expressed as the mean ± standard error for five
to nine mice per group. Asterisks indicate data that were significantly
different for control and anti-IL-12-treated mice as determined by
Student's t test (P 0.05).
|
|
The absolute numbers of CD119
+ cells were similar in lungs
of control and IL-12-depleted animals, except on day 5, when the
latter
group displayed a significant decrease of 1.5-fold (
P
0.024). The number of cells expressing MHC II molecules increased
over those for noninfected mice in both rat IgG- and anti-IL-12-treated
mice as infection progressed, but the MHC II
+ cells
observed after IL-12 neutralization were significantly
decreased
compared to those for controls on days 3 (2-fold;
P 
0.039), 5 (2.5-fold;
P 
0.010), and 7 (1.7-fold;
P 
0.028).
Changes in cell surface densities of MHC II, CD80, and CD86
molecules.
Initially we determined if infection with H. capsulatum altered the relative densities of surface MHC II, CD80,
CD86, and Mac-1 molecules. To accomplish this, MFI values were compared between naive (noninfected) and rat IgG-treated mice on days 3, 5, 7, 10, 14, and 21 of infection. The densities of surface CD80 and Mac-1
molecules were similar in the two groups through day 7, whereas CD86
expression was increased approximately 2.5-fold on days 3 and 5 (P
0.05). The MFI for MHC II expression decreased three- to fourfold in the rat IgG-treated group when compared to
noninfected (naive) animals (P
0.02) on all days
analyzed. Therefore, no changes in surface expression of CD80 and Mac-1 were observed, CD86 expression increased, and MHC II expression decreased during the first week.
To determine the effect of reduced IL-12 levels on the relative density
of surface molecules, the fold increase in MFI values
between rat IgG-
and anti-IL-12-treated mice was compared (Fig.
3). After IL-12 neutralization, the
density of CD80 on lung cells
was similar to that in rat IgG-treated
mice on days 3 and 5 but
was decreased 1.5- to 2.0-fold on days 7 and
10 (
P 
0.02). CD86
densities were significantly
decreased on lung cells isolated
from anti-IL-12-treated mice on days
5, 7, and 10 (
P 
0.03),
whereas surface expression of
Mac-1 was increased on all days
analyzed (
P 
0.05).
Although the density measurements for MHC
II differed between rat IgG-
and anti-IL-12-treated animals, none
of these differences was
significant (
P 
0.05).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Alteration in surface antigen expression after IL-12
neutralization. The density of expression for each marker was measured
by MFI, and the fold increase in these values over those for the
negative population was calculated. The data from two experiments were
expressed as the mean ± standard error for five to nine mice per
group. Asterisks indicate data that were significantly different for
control and anti-IL-12-treated mice as determined by Student's
t test (P 0.05).
|
|
Cellular phenotype during reduced fungal burden.
It was
possible that the changes observed in cell surface phenotype after
IL-12 neutralization were caused by an increased fungal burden. To
address this hypothesis, mice treated with anti-IL-12 were infected
with an inoculum of H. capsulatum (0.6 × 106) that approximated the burden in control mice during
days 7 to 14. We did not include a group of rat IgG-treated animals
injected with 0.6 × 106 yeasts, since the purpose of
this experiment was to ascertain if the fungal burden or anti-IL-12
influenced the inflammatory response. The lungs of mice that received
the reduced number of yeasts and anti-IL-12 contained 1.91 × 106 ± 0.70 × 106 CFU on day 10 of
infection. This value was approximately the same (P
0.05) as that observed in controls on day 7 (2.4 × 106 ± 0.45 × 106).
When the fungal burden was matched, the absolute numbers of cells
infiltrating lungs in control mice and anti-IL-12-treated
mice infected
with 0.6 × 10
6 yeasts were comparable (Table
1). The
total numbers of Mac-1
+ and Thy-1
+ cells were
similar in lungs of control mice on day 7 and in those
infected with
0.6 × 10
6 yeasts on day 10 (Fig.
4). The number of T cells from mice
treated
with anti-IL-12 and exposed to 2.5 × 10
6
yeasts on day 10 were also the same, although the fungal burden
was
increased fourfold over that in controls.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of the total numbers of Mac-1+
and Thy-1+ lung cells in mice given anti-IL-12 and infected
with different numbers of yeasts. The total numbers of lineage-specific
cells in lungs of mice infected with 2.5 × 106 yeasts
and treated with rat IgG or anti-IL-12 and mice administered anti-IL-12
and infected with 0.6 × 106 yeast cells were
determined by flow cytometry. The data from two experiments were
expressed as the mean (± standard error) of the numbers of cells
expressing each marker for five to nine mice per group. Data for day 0 were from uninfected mice (n = 5). Asterisks indicate
data that were significantly different for control and
anti-IL-12-treated groups receiving 2.5 × 106 yeasts
as determined by Student's t test (P 0.05).
|
|
The pattern of increased cell numbers for CD80, CD86, CD119, and
MHC II observed in control mice infected with 2.5 × 10
6 yeasts (Fig.
1) was similar in anti-IL-12-treated mice
infected
with 0.6 × 10
6 yeasts (data not shown). The
numbers of CD80-, CD86-, and CD119-bearing
cells were comparable in
anti-IL-12-treated mice infected with
2.5 × 10
6 or
0.6 × 10
6 yeasts on days 7 and 10, respectively, but
MHC II
+ cells were reduced in the animals infected with the
reduced inoculum
(
P 
0.045).
Distribution of CD80+ and CD86+ cells among
different cell lineages.
Since CD80 and CD86 are expressed by
multiple cell types, data from two-color immunofluorescent analyses of
surface expression of these molecules versus the lineage markers Thy-1
(T cells), B220 (B cells), Mac-1 (myeloid cells), and Gr-1
(granulocytes) were calculated as the total number of lineage-specific
cells that express these markers during histoplasmosis in control and IL-12-neutralized animals (Fig. 5). The
majority of CD80+ cells on day 3 of infection were
Mac-1+, and most coexpressed the granulocyte marker Gr-1.
This myeloid cell dominance for CD80+ cells continued
through day 7 and then declined as the number of CD80+ T
cells increased on days 10 and 14 of infection (Fig. 5A). The distribution of CD80+ cells in IL-12-depleted mice was
dramatically different (Fig. 5B). The large increase in
Mac-1+ and Gr-1+ cells that expressed CD80 was
delayed until after day 5 and peaked on day 7, when 25% of all
Mac-1+ cells in lungs coexpressed CD80. In contrast, cells
expressing both markers in controls on days 3 and 5 represented 10% of
the total Mac-1+ cells. Although the total T-cell
population on day 10 was increased after IL-12 neutralization, the
number of CD80+ T cells was greatly diminished (ninefold
less than controls) (Fig. 5B).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Lineage distribution of CD80+ and
CD86+ lung cells. The expression of CD80 and CD86 on
myeloid-lineage cells (Mac-1+), T cells
(Thy-1+), and B cells (B220+) was determined by
two-color immunofluorescence analysis. The data from two experiments
were expressed as the mean of the total number of lineage-specific
cells that coexpress CD80 or CD86 from lungs of naive mice
(n = 5) and infected mice from days 3 to 21 of
infection (n 6 per group). CD80+
lineage+ data (A, B, and C) and CD86+
lineage+ values (D, E, and F) were determined for rat
IgG-treated mice infected with 2.5 × 106 yeasts (A
and D), mice given anti-IL-12 and 2.5 × 106 yeasts (B
and E), and mice given anti-IL-12 and 0.6 × 106 (C
and F).
|
|
The distribution of CD86 on lineage-specific cells was similar to that
of CD80. The initial increase in cells expressing this
marker from days
3 to 7 was in cells of myeloid lineage, followed
by an increase in
Thy-1
+ CD86
+ cells between days 7 and 14 (Fig.
5D). The difference in expression
of CD80 and CD86 was that 1.5-fold
more myeloid-lineage cells
and 2- to 3-fold more T cells expressed
CD86. After IL-12 neutralization,
the Mac-1/GR-1
+
CD86
+ subset increased between days 5 and 7 (Fig.
5E), but
fewer cells
expressed both markers than cells that coexpressed CD80.
Numbers
of Thy-1
+ CD86
+ cells were slightly
greater than those of CD80
+ T cells on day 10 after IL-12
neutralization, but both populations
were approximately ninefold less
than those in lungs of control
animals.
A phenotypic analysis of lung cells isolated from mice infected with a
reduced yeast burden (0.6 × 10
6) revealed a different
cellular distribution of CD80 and CD86
than that observed in animals
infected with 2.5 × 10
6 yeasts. The dominant
populations expressing both markers, Mac-1
+ and
Gr-1
+, were observed between days 5 and 10 of infection,
declined between
days 10 to 14, and increased on days 14 and 21 (Fig.
5C and F).
A major difference in lung phenotype was observed in the
T-cell
populations. Thirteen percent of the total number of T cells
isolated
from animals given 0.6 × 10
6 yeasts
expressed CD80 and 30% expressed CD86 during the peak
on day 21, whereas 3 to 5% of T cells in lungs from animals receiving
2.5 × 10
6 yeasts expressed these markers on day
10.
Effect of blocking CD80 and CD86 on fungal burden.
Since
both CD80 and CD86 were upregulated during infection with H. capsulatum and expression of these molecules was altered in
animals treated with anti-IL-12, we determined if blocking of either or
both of these CD28 ligands would alter the outcome of disease. Lungs
and spleens were removed from animals treated with rat IgG or MAb to
CD80, CD86, or both on days 7, 14, and 21 of infection, and the fungal
burden was determined by CFU analysis. Although there was a slight
decrease in the burden on day 7 in both spleens and lungs of all
groups, none of these values were significantly different from those
for controls treated with rat IgG (P
0.05) (Table
2).
The fungal burden in lungs and spleens of mice after IL-12
neutralization was significantly increased over control levels.
Since
the number of CD80-bearing cells was increased after IL-12
neutralization, we determined if administration of anti-CD80 and
anti-IL-12 modulated the fungal burden. The CFU were significantly
decreased (
P 
0.01), by 2.5-fold, when CD80 was
blocked (Table
2).
To determine if modulation of cytokine levels correlated with the
reduction in CFU, supernatants from lungs of mice treated
with rat IgG,
anti-IL-12, anti-CD80, or both anti-IL-12 and anti-CD80
were analyzed
for the amounts of IFN-

, IL-4, TNF-

, and GM-CSF
(Table
3). TNF-

levels in the lungs were
similar among all groups.
GM-CSF levels in all three experimental
groups were significantly
decreased compared to those in infected
controls (
P 
0.005),
but the values for
anti-CD80-treated, IL-12-neutralized, and anti-CD80-
and
anti-IL-12-treated animals were comparable to each other.
IL-4 levels
in lungs from control animals and IL-12-neutralized
mice were not
significantly different, whereas treatment with
anti-CD80 reduced IL-4
levels in both infected controls given
rat IgG and mice given
anti-IL-12 (
P 
0.01 and
P 
0.03,
respectively).
In addition, IL-4 levels in animals treated with both
antibodies
were reduced compared with those in mice treated with IL-12
alone
(
P 
0.006). IFN-

was slightly reduced when
CD80 was blocked
(
P 
0.04), whereas cytokine levels
in the experimental groups
given anti-IL-12 were four- to fivefold
decreased (
P 
0.007)
compared to those in the rat
IgG-treated controls. The ratios
of IFN-

to IL-4 were 1,030 and
1,070 for the control and anti-CD80-treated
groups, respectively,
whereas these ratios were greatly reduced
after IL-12 neutralization
(to 284 and to 330) when MAb to both
IL-12 and CD80 were administered.
Regardless of the decreased fungal burden and reduced IL-4 levels
after anti-CD80 treatment in IL-12-neutralized mice, seven
of seven
anti-IL-12-treated mice and seven of eight mice treated
with anti-IL-12
and anti-CD80 succumbed to infection by day 16.
The mean survival times
were 13.1 ± 0.9 days for the anti-IL-12
treated group and
12.8 ± 0.6 days for animals given both
MAb.
 |
DISCUSSION |
The principal goal of this study was to further explore the
effects of IL-12 neutralization in lungs of mice infected with H. capsulatum. Emphasis was placed on determining alterations in the
surface expression of molecules responsible for interactions between T
cells and antigen-presenting cells, namely, CD80, CD86, and MHC II, as
well as the IFN-
receptor (CD119). After IL-12 neutralization, there
were perturbations in the influx of myeloid and T cells and reductions
in the total numbers of cells that express CD86 and MHC II.
In association with the increased fungal burden in mice given MAb to
IL-12, there was a dramatically different inflammatory response. Two
major alterations in the lineage-cell distribution in lungs of
IL-12-depleted mice were (i) the large increase of myeloid cells,
especially polymorphonuclear leukocytes, into the lung after day 5 of
infection and (ii) the almost complete absence of T-cell infiltration
during the first week. The lack of endogenous IL-12 clearly modulated
the evolution of the inflammatory response. That IL-12 influences
pulmonary inflammation has been demonstrated in a model of
cryptococcosis. Administration of exogenous IL-12 increases both
mononuclear leukocyte infiltration into lungs of mice and the levels of
the chemoattractants macrophage inflammatory protein-1 alpha and
monocyte chemotactic protein 1 (14).
The T-cell influx in lungs of infected controls peaks during the
second week of infection, while the numbers of myeloid cells decrease
(5). After IL-12 neutralization, the expected rise in the
number of T cells in lungs was not observed. The failure of these cells
to migrate into infected lungs could have been caused by a disrupted
chemokine response, since T-cell influx into inflammatory sites can be
controlled by multiple chemokines and their receptors (29).
Although evidence directly linking endogenous IL-12 generation and
T-cell chemotaxis is scarce, one study reported that IL-12 upregulates
E- and P-selectin ligands on T cells, thus facilitating recruitment
into inflamed tissue (31).
IL-12 neutralization affected cells expressing CD80 and CD86
differently. The numbers of CD80+ cells were fourfold
greater on days 7 and 10, but the surface density was twofold less. The
differences in CD86+ cells were observed on days 3 and 5, when a threefold reduction in total numbers and a significant decrease
in surface density were detected after IL-12 neutralization. Since
there was a decrease in both the numbers of CD86+ cells and
their surface density, the availability of CD86 molecules for binding
to CD28 was definitely less than in controls. This reduction during the
first week indicated that expression of this molecule was influenced by
the IFN-
deficiency induced by administration of MAb to IL-12.
Since IFN-
is a potent stimulator of MHC II surface expression
(9, 12, 21), we tested the effect of IL-12 neutralization on
the number of cells that expressed MHC II and the density of expression. H. capsulatum infection produced a
downregulation in surface MHC II molecules on lung cells isolated from
rat Ig- and anti-IL-12-treated mice compared to noninfected controls. Although the number of MHC II-bearing cells in infected
anti-IL-12-treated mice was markedly less than that in infected
controls on days 3 to 7, there were no significant differences in MFI
values between the two groups. Therefore, decreased levels of IFN-
affected the numbers of MHC II+ cells but not the density
per cell. These data strongly suggest that IFN-
is not the sole
regulator of MHC II expression in H. capsulatum-infected
mice. TNF-
and GM-CSF, two other cytokines that stimulate MHC II
expression, may have compensated for the IFN-
deficiency (12,
21).
An important consideration for these studies was to determine if
the altered inflammatory response in mice administered anti-IL-12 and
injected with 2.5 × 106 yeasts was simply a
consequence of an increased fungal burden or the lack of IL-12 and
IFN-
. To address these issues, we designed an experiment in which
the CFU in lungs of infected controls would be commensurate with those
in mice receiving MAb to IL-12 during the early phases of infection
(
10 days). An inoculum size of 0.6 × 106 was
selected and given to mice treated with anti-IL-12. The marked elevations in myeloid cells that were observed in mice infected with
2.5 × 106 yeasts and given anti-IL-12 were not
apparent in the group injected with anti-IL-12 and the lower inoculum.
Likewise, the variation in the number of CD80+ and
CD86+ cells was no longer detected. For these cell
populations, the fungal burden stimulated the fluctuations. On the
other hand, the MHC II+ cell numbers were significantly
lower in the group receiving anti-IL-12 and the lower inoculum of
H. capsulatum. The decline in this cell population was
likely to be modified by the deficiency in IL-12 and IFN-
rather
than by a change in the number of yeasts recovered from lungs.
The influx of T cells appeared to be dependent on the fungal burden,
since their numbers were similar when the burdens were matched (day 7 in infected controls and day 10 for mice anti-IL-12 treated and
inoculated with 0.6 × 106 yeasts). Yet, the lungs of
anti-IL-treated mice infected with 2.5 × 106 yeasts
also contained similar numbers of T cells on day 10, when the CFU were
fourfold greater. However, the subset distribution of T cells in this
group of mice was altered. CD86+ Thy-1+ cells
were decreased compared to those in infected controls and mice given
anti-IL-12 and infected with 0.6 × 106 yeasts. It is
possible that the large cellular influx triggered on day 10 in mice
IL-12 neutralized and infected with 2.5 × 106 yeasts
resulted in a transient migration of T cells and that their numbers are
not as important as their phenotype.
There are conflicting data on the function of CD80 and CD86 in
promoting differentiation of a T-helper cell type 1 (Th1) versus a Th2
response. In experimental allergic encephalomyelitis (15) and bronchial asthma (27) the interaction between CD80 and
CD28 triggers differentiation of Th1 cells that produce IFN-
, and CD86 is responsible for generation of Th2 cells and IL-4 production. Subsequent data revealed that CD86-transfected CHO cells preferentially induce IL-4-producing cells (11) or that there is no skewing of T cells to a Th1 or Th2 phenotype by either CD80 or CD86
(19).
Studies have shown that induction of Th1 or Th2 cytokines in animals
given MAb to CD80 or CD86 varies with the model of infection. Blocking
of CD86 reduces IL-4 levels and the burden in mice infected with either
Leishmania major (3, 6) or Candida
albicans (17), whereas blocking of both CD80 and CD86
results in reduced IFN-
levels but has no effect on the burden of
Listeria monocytogenes (32). In experimental
schistosomiasis (28) and borreliosis (23) CD86
blockade reduces IL-4 levels, but it reduces the burden only during
schistosomiasis. A common factor in most of these disease models is
that inhibition of CD86 appears to reduce IL-4 levels. However,
administration of anti-CD86 increases the numbers of IL-4- and
IFN-
-secreting cells in mice infected with Leishmania donovani (18). In contrast, anti-CD80 treatment reduced
IL-4 levels in control and anti-IL-12-treated mice infected with
H. capsulatum. Thus, the effects of CD80 and CD86 on
cytokine production differ from those in other experimental models.
To determine if CD80 and CD86 influenced the course of disease, groups
of infected mice were treated i.n. with MAb to these molecules that
have been reported to block effector cell function (27).
Treatment with MAb to CD80, CD86, or both reduced the burden only
slightly compared to that in rat Ig-treated controls. Thus, blockade of
CD80 and CD86 did not enhance an efficient host resistance mechanism. A
significant decrease in burden was observed in animals treated with
anti-CD80 and anti-IL-12. Under these conditions, the reduction in
fungal burden was more dramatic, because host control of histoplasmosis
was blunted in the presence of anti-IL-12, and the beneficial effect of
CD80 blockade was observed only in a model where the host response is
impaired. A similar result was reported for resistant mice infected
with L. major (6). In this study the burden was
slightly reduced after administration of CTLA4-Ig, a reagent that
blocks both CD80 and CD86, but the greater effect was in the
significant reduction of burden by the same treatment in susceptible mice.
Disease progression may be controlled by altering the relative
levels of cytokines that are required for healing and those that
exacerbate infection (8, 10, 24, 25). That the balance between Th1 and Th2 cytokines, rather than the absolute values, is
important for disease amelioration has been shown in a model of
leishmaniasis (20). Susceptable BALB/c mice that lack the IL-4 receptor alpha chain do not increase IFN-
levels over those in
wild-type animals, yet infection is partially controlled. This study
concludes that even low levels of IFN-
can have a healing effect in
the absence of IL-4. During histoplasmosis, anti-IL-12 treatment
changed the ratio of IFN-
to IL-4 but not the absolute levels of the
latter. The reduction in IL-4 caused by anti-CD80 treatment slightly
improved the balance between the two cytokines and, as a consequence,
partially restored host resistance. Regardless of any reduction in
burden observed, the outcome of disease was the same. In the presence
or absence of anti-CD80, anti-IL-12 recipients died with comparable
mean survival times. Therefore, the impact of CD80 blockade was
transient and failed to completely restore protective immunity.
The present study demonstrated that IL-12 neutralization and
infection with H. capsulatum altered the inflammatory
response by greatly enhancing the myeloid cell influx into mouse lungs and greatly reducing the T-cell population, the numbers of cells that
express MHC II molecules, and the numbers and density of the
costimulatory molecule CD86. Alterations in these two surface antigens,
which function in antigen presentation and as a second signal for
activation of T cells, respectively, were observed early in infection
when the effects of anti-IL-12 treatment are detrimental. The CD86
costimulatory molecule was not entirely responsible for protective
immunity but may be part of a mechanism of T-cell activation and
recruitment necessary for establishing an adaptive immune response.
 |
ACKNOWLEDGMENTS |
This work was supported by Public Health Service grants AI-42747
and AI-34361 and by a Merit Review Award from the Department of
Veterans Affairs.
We thank George Brunner for excellent technical assistance and Simon
Newman, Carlos Subauste, and Francisco Gomez for their critical review
of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Internal Medicine, Division of Infectious Diseases, University of
Cincinnati Medical Center, P.O. Box 670560, Cincinnati, OH 45267-0560. Phone: (513) 558-4704. Fax: (513) 558-2089. E-mail:
deepegs{at}emailuc.edu.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Allendoerfer, R.,
G. P. Boivin, and G. S. Deepe, Jr.
1997.
Modulation of immune responses in murine pulmonary histoplasmosis.
J. Infect. Dis.
175:905-914[Medline].
|
| 2.
|
Allendoerfer, R., and G. S. Deepe, Jr.
1997.
Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice.
Infect. Immun.
65:2564-2569[Abstract].
|
| 3.
|
Brown, J. A.,
R. G. Titus,
N. Nabavi, and L. H. Glimcher.
1996.
Blockade of CD86 ameliorated Leishmania major infection by down-regulating the Th2 response.
J. Infect. Dis.
174:1303-1308[Medline].
|
| 4.
|
Bullock, W. E., and S. D. Wright.
1987.
Role of the adherence-promoting receptors, CR3, LFA-1, and p150,95, in binding of Histoplasma capsulatum by human macrophages.
J. Exp. Med.
165:195-210[Abstract/Free Full Text].
|
| 5.
|
Cain, J. A., and G. S. Deepe, Jr.
1998.
Evolution of the primary immune response to Histoplasma capsulatum in murine lungs.
Infect. Immun.
66:1473-1481[Abstract/Free Full Text].
|
| 6.
|
Corry, D. B.,
S. L. Reiner,
P. S. Linsley, and R. M. Lockley.
1994.
Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis.
J. Immunol.
153:4142-4148[Abstract].
|
| 7.
|
Deepe, G. S., Jr.
1994.
The immune response to Histoplasma capsulatum: unearthing its secrets.
J. Lab. Clin. Med.
123:201-205[Medline].
|
| 8.
|
Deepe, G. S., Jr., and R. A. Seder.
1998.
Molecular and cellular determinants of immunity to Histoplasma capsulatum.
Res. Immunol.
149:397-406[CrossRef][Medline].
|
| 9.
|
Ding, L.,
P. S. Linsley,
L. Huang,
R. N. Germain, and E. M. Shevach.
1993.
IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.
J. Immunol.
151:1224-1234[Abstract].
|
| 10.
|
Erb, K. J.,
C. Blank, and H. Moll.
1996.
Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response.
Immunol. Cell. Biol.
74:239-244[Medline].
|
| 11.
|
Freeman, G. J.,
V. A. Boussiotis,
A. Anumanthan,
G. M. Bernstein,
X. Ke,
P. D. Rennert,
G. S. Gray,
J. G. Gribben, and L. M. Nadler.
1995.
B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.
Immunity
2:523-532[CrossRef][Medline].
|
| 12.
|
Glimcher, L. H., and C. J. Kara.
1992.
Sequences and factors: a guide to MHC class-II transcription.
Annu. Rev. Immunol.
10:13-49[CrossRef][Medline].
|
| 13.
|
Goding, J. W.
1976.
Conjugation of antibodies with fluorochromes: modification to the standard methods.
J. Immunol. Methods
13:215-225[CrossRef][Medline].
|
| 14.
|
Kawakami, K.,
M. H. Qureshi,
T. Zhang,
Y. Koguchi,
K. Shibuya,
S. Naoe, and A. Saito.
1999.
Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans.
Clin. Exp. Immunol.
117:113-122[CrossRef][Medline].
|
| 15.
|
Kuchroo, V. K.,
M. P. Das,
J. A. Brown,
A. M. Ranger,
S. S. Zamvil,
R. A. Sobel,
H. L. Weiner,
N. Nabavi, and L. M. Glimcher.
1995.
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.
Cell
80:707-718[CrossRef][Medline].
|
| 16.
|
McKinney, M. M., and A. Parkinson.
1987.
A simple non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid.
J. Immunol. Methods
96:271-278[CrossRef][Medline].
|
| 17.
|
Mencacci, A.,
E. Cenci,
G. Del Sero,
C. F. d'Ostiani,
P. Mosci,
G. Trinchieri,
L. Adorini, and L. Romani.
1998.
IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection.
J. Immunol.
161:6228-6237[Abstract/Free Full Text].
|
| 18.
|
Murphy, M. L.,
C. R. Engwerda,
P. M. A. Gorak, and P. M. Kaye.
1997.
B7-2 blockade enhances T cell responses to Leishmania donovani.
J. Immunol.
159:4460-4466[Abstract].
|
| 19.
|
Natesan, M.,
Z. Razi-Wolf, and H. Reiser.
1996.
Costimulation of IL-4 production by murine B7-1 and B7-2 molecules.
J. Immunol.
156:2783-2791[Abstract].
|
| 20.
|
Noben-Trauth, N.,
W. E. Paul, and D. L. Sacks.
1999.
IL-4 and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains.
J. Immunol.
162:6132-6140[Abstract/Free Full Text].
|
| 21.
|
Panek, R. B., and N. Benveniste.
1995.
Class II MHC gene expression in microglia. Regulation by the cytokines IFN- , TNF- , and TGF- .
J. Immunol.
154:2846-2854[Abstract].
|
| 22.
|
Scheid, M. P., and D. Triglia.
1979.
Further description of the Ly-5 system.
Immunogenetics
9:423-432[CrossRef].
|
| 23.
|
Shanafelt, M. C.,
I. Kang,
S. W. Barthold, and L. K. Bockenstedt.
1998.
Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.
Infect. Immun.
66:266-271[Abstract/Free Full Text].
|
| 24.
|
Szalay, G.,
C. H. Ladel,
C. Blum, and S. H. E. Kaufmann.
1996.
IL-4 neutralization or TNF- treatment ameliorate disease by an intracellular pathogen in IFN- receptor-deficient mice.
J. Immunol.
157:4746-4750[Abstract].
|
| 25.
|
Tonnetti, L.,
R. Spaccepelo,
E. Cenci,
A. Mencacci,
P. Puccetti,
R. L. Coffman,
F. Bistoni, and R. Romani.
1995.
Interleukin-4 and -10 exacerbate candidiasis in mice.
Eur. J. Immunol.
25:1559-1565[Medline].
|
| 26.
|
Trinchieri, G.
1997.
Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN- ).
Curr. Opin. Immunol.
9:17-23[CrossRef][Medline].
|
| 27.
|
Tsuyuki, S.,
J. Tsuyuki,
K. Einsle,
M. Kopf, and A. J. Coyle.
1997.
Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness.
J. Exp. Med.
185:1671-1679[Abstract/Free Full Text].
|
| 28.
|
Villanueva, P. O. F.,
H. Reiser, and M. J. Stadecker.
1994.
Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10.
J. Immunol.
153:5190-5199[Abstract].
|
| 29.
|
Ward, S. G., and J. Westwick.
1998.
Chemokines: understanding their role in T-lymphocyte biology.
Biochem. J.
333:457-470.
|
| 30.
|
Wu-Hsieh, B.
1989.
Relative susceptibilities of inbred mouse strains C57BL/6 and A/J to infection with Histoplasma capsulatum.
Infect. Immun.
57:3788-3792[Abstract/Free Full Text].
|
| 31.
|
Xie, H.,
Y. C. Lim,
F. W. Luscinskas, and A. H. Lichtman.
1999.
Acquisition of selectin binding and peripheral homing properties by CD4(+) and CD8(+) T cells.
J. Exp. Med.
189:1765-1776[Abstract/Free Full Text].
|
| 32.
|
Zhan, Y., and C. Cheers.
1996.
Either B7-1 or B7-2 is required for Listeria monocytogenes-specific production of gamma interferon and interleukin-2.
Infect. Immun.
64:5349-5441[Abstract].
|
| 33.
|
Zhou, P.,
M. C. Sieve,
J. Bennett,
K. J. Kwon-Chung,
R. P. Tewari,
R. T. Gazzinelli,
A. Sher, and R. A. Seder.
1995.
IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN- .
J. Immunol.
155:785-795[Abstract].
|
Infection and Immunity, April 2000, p. 2069-2076, Vol. 68, No. 4
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Deepe, G. S. Jr, Gibbons, R. S., Smulian, A. G.
(2008). Histoplasma capsulatum manifests preferential invasion of phagocytic subpopulations in murine lungs. J. Leukoc. Biol.
84: 669-678
[Abstract]
[Full Text]
-
Coltri, K. C., Oliveira, L. L., Pinzan, C. F., Vendruscolo, P. E., Martinez, R., Goldman, M. H., Panunto-Castelo, A., Roque-Barreira, M.-C.
(2008). Therapeutic Administration of KM+ Lectin Protects Mice Against Paracoccidioides brasiliensis Infection via Interleukin-12 Production in a Toll-Like Receptor 2-Dependent Mechanism. Am. J. Pathol.
173: 423-432
[Abstract]
[Full Text]
-
Shi, L., Albuquerque, P. C., Lazar-Molnar, E., Wang, X., Santambrogio, L., Gacser, A., Nosanchuk, J. D.
(2008). A Monoclonal Antibody to Histoplasma capsulatum Alters the Intracellular Fate of the Fungus in Murine Macrophages. Eukaryot Cell
7: 1109-1117
[Abstract]
[Full Text]
-
Mencacci, A., Montagnoli, C., Bacci, A., Cenci, E., Pitzurra, L., Spreca, A., Kopf, M., Sharpe, A. H., Romani, L.
(2002). CD80+Gr-1+ Myeloid Cells Inhibit Development of Antifungal Th1 Immunity in Mice with Candidiasis. J. Immunol.
169: 3180-3190
[Abstract]
[Full Text]